Immunovant’s Batoclimab Fails Phase 3 Trial for Thyroid Eye Disease
The landscape for treating Thyroid Eye Disease (TED), a painful and vision-threatening autoimmune condition, has seen significant innovation in recent years. However, the path forward is not without its setbacks. In a significant development, Immunovant Inc. has announced that its lead investigational drug, batoclimab, did not meet its primary endpoint in a pivotal Phase 3 clinical trial. This news shifts the spotlight squarely onto the company’s next-generation candidate, IMVT-1402, and raises important questions about the future of FcRn inhibition in treating TED.
A High-Stakes Trial Falls Short
The Phase 3 trial, named ASCEND GO 2, was designed to evaluate the efficacy and safety of batoclimab in patients with active, moderate-to-severe TED. The primary endpoint was the percentage of patients achieving a Clinical Activity Score (CAS) of 0 or 1—indicating minimal or no inflammation—without the need for rescue treatment at Week 12.
According to the topline results, the trial did not achieve statistical significance on this primary measure. While the company reported that batoclimab was generally well-tolerated with a safety profile consistent with prior studies, the failure to hit the key efficacy marker represents a major disappointment for patients and the company alike. This outcome is particularly striking given the earlier promise shown by batoclimab, an anti-FcRn monoclonal antibody designed to lower pathogenic IgG antibodies, in other autoimmune conditions.
Understanding the Mechanism: Why FcRn Blockade Was a Promising Avenue
To grasp the significance of this trial result, it’s essential to understand the science behind the therapy. Thyroid Eye Disease is primarily driven by autoantibodies that target the thyroid-stimulating hormone receptor (TSHR). These rogue antibodies incite inflammation and tissue remodeling behind the eyes, leading to proptosis (eye bulging), double vision, pain, and in severe cases, vision loss.
Batoclimab works by blocking the Neonatal Fc Receptor (FcRn). This receptor normally protects IgG antibodies (including the harmful ones in TED) from degradation, recycling them back into circulation. By inhibiting FcRn, batoclimab aims to accelerate the breakdown of all IgG antibodies, thereby reducing the levels of the disease-causing autoantibodies. This mechanism has proven successful with other FcRn inhibitors in conditions like generalized myasthenia gravis, creating optimism for its application in TED.
Potential Reasons Behind the Missed Endpoint
The scientific community is now left to ponder why this theoretically sound approach did not translate to a clear clinical win in ASCEND GO 2. Several hypotheses are emerging:
- Timing and Disease Chronicity: The inflammatory phase of TED can be variable. It’s possible that the 12-week primary endpoint did not allow enough time for the drug’s IgG-lowering effect to fully translate into observable reductions in inflammation and CAS scores.
- Endpoint Sensitivity: The CAS, while a standard measure, is a composite score. A drug might be having a meaningful biological effect on certain components (like pain or redness) that is diluted when measured against the stringent goal of a 0 or 1 score.
- Patient Population: Differences in the trial’s patient demographics or disease characteristics compared to earlier, successful trials of other TED therapies could have influenced the outcome.
- IgG Reduction vs. Specific Antibody Clearance: FcRn blockade non-selectively lowers all IgG. It remains a topic of study whether a broad reduction is as effective as directly targeting the specific pathogenic pathway (as Tepezza® does with the IGF-1R receptor).
The Strategic Pivot: All Eyes Now on IMVT-1402
Despite the setback with batoclimab, Immunovant’s story is far from over. The company has been clear that its strategic focus is rapidly shifting to IMVT-1402, its next-generation anti-FcRn asset. This is not merely a backup plan but represents what the company believes is a potentially superior therapy.
IMVT-1402 is engineered to achieve a similar level of pathogenic IgG reduction as batoclimab but with a key difference: it aims to do so without causing a significant increase in LDL cholesterol. Transient increases in LDL (“bad”) cholesterol have been a class-effect observation with first-generation FcRn inhibitors, including batoclimab. By minimizing this effect, IMVT-1402 could offer an improved safety and tolerability profile, which is crucial for chronic autoimmune disease management.
What’s Next for Immunovant’s Pipeline?
The batoclimab result accelerates Immunovant’s pipeline transition. The company has indicated that:
- Development of batoclimab in TED will be discontinued.
- Resources will be reallocated to expedite the development of IMVT-1402 across multiple indications.
- A Phase 2b trial for IMVT-1402 in Graves’ disease (the autoimmune disorder underlying TED) is already underway, with topline data expected in late 2024.
- Plans for a pivotal Phase 3 program in TED using IMVT-1402 are being prioritized.
Broader Implications for the TED Treatment Landscape
This development has ripple effects beyond Immunovant. The TED treatment market, once with limited options, has become competitive with the success of Horizon Therapeutics’ Tepezza® (teprotumumab). The failure of a high-profile candidate like batoclimab underscores the unique clinical challenges in treating TED and validates the difficulty of successfully navigating Phase 3 trials in this space.
For patients, it means a delay in having a potential new treatment option. However, the continued investment and rapid pivot to a next-generation candidate demonstrate that FcRn inhibition remains a viable and actively pursued pathway. The potential for an effective therapy that avoids the LDL cholesterol effect could still represent a meaningful future advance.
Conclusion: A Setback, Not an Endpoint
Immunovant’s Phase 3 trial failure for batoclimab in Thyroid Eye Disease is a sobering reminder of the inherent risks in drug development, even for promising mechanisms. The unmet need for safe, effective, and convenient TED therapies remains high.
While the batoclimab chapter in TED is closing, the company’s narrative is swiftly turning the page. The focus now intensifies on IMVT-1402, which carries the hope of delivering the benefits of FcRn blockade without a key tolerability concern. The upcoming data from the Graves’ disease trial will be the next critical milestone, offering an early signal of whether this next-generation candidate can succeed where its predecessor fell short. For the TED community and Immunovant, the journey toward a new treatment continues, albeit on a slightly altered path.
